Open Access
REVIEW
SEMA MISIR1,*, SERAP OZER YAMAN2, NINA PETROVIĆ3,4, CEREN SUMER5, CEYLAN HEPOKUR1, YUKSEL ALIYAZICIOGLU2
Oncology Research, Vol.30, No.4, pp. 157-172, 2022, DOI:10.32604/or.2022.027547
Abstract Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of
cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for
BC treatment. One of the significant challenges during the treatment of BC represents resistance to
chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment.
Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a
large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends.
Accumulating evidence… More >
Open Access
ARTICLE
DIEGO HERNANDEZ1,*, CHIH-YUAN CHENG1,2, KARLA HERNANDEZ-VILLAFUERTE1, MICHAEL SCHLANDER1,2
Oncology Research, Vol.30, No.4, pp. 173-185, 2022, DOI:10.32604/or.2022.027262
Abstract Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate
for men and women respectively in Germany. Yet, the role of comorbid illnesses in lung cancer patient prognosis is still
debated. We analyzed administrative claims data from one of the largest statutory health insurance (SHI) funds in
Germany, covering close to 9 million people (11% of the national population); observation period was from 2005 to
2019. Lung cancer patients and their concomitant diseases were identified by ICD-10-GM codes. Comorbidities were
classified according to the Charlson Comorbidity Index (CCI). Incidence, comorbidity prevalence and… More >
Open Access
ARTICLE
HUAQING MO#, JINGYI SHEN#, YUXIAO ZHONG, ZENAN CHEN, TONG WU, YANYU LV*, YANYAN XIE, YANRONG HAO*
Oncology Research, Vol.30, No.4, pp. 187-199, 2022, DOI:10.32604/or.2022.027534
Abstract Nasopharyngeal carcinoma (NPC) is the most prevalent human primary malignancy of the head and neck, and
the presence of vasculogenic mimicry (VM) renders anti-angiogenic therapy ineffective and poorly prognostic. However,
the underlying mechanisms are unclear. In the present study, we used miR-940 silencing and overexpression for in vitro
NPC cell EdU staining, wound healing assay and 3D cell culture assay, and in vivo xenograft mouse model and VM
formation to assess miR-940 function. We found that ectopic miR-940 expression reduced NPC cell proliferation,
migration and VM, as well as tumorigenesis in vivo. By bioinformatic analysis, circMAN1A2 was identified as a… More >
Open Access
ARTICLE
YONGKANG SHI, JUN MA, KE CHEN, BIN CHEN*
Oncology Research, Vol.30, No.4, pp. 201-210, 2022, DOI:10.32604/or.2022.027584
Abstract 5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for various cancers. However, the drug
resistance developed by tumor cells hinders the therapeutic effect. Konjac glucomannan (KGM) is indicated to
sensitize 5-FU-resistant hepatocellular carcinoma (HCC) cells to 5-FU. In our study, we found that KGM or 5-FU
treatment alone did not affect the malignant cell behaviors and endoplasmic reticulum (ER) stress of 5-FU-resistant
HCC cells or HepG2/5-FU and Bel-7402/5-FU cells, while cotreatment with KGM and 5-FU significantly facilitated
HCC cell apoptosis and ER stress and suppressed cell proliferation potential and migration abilities. Moreover, we
explored the underlying mechanism by which KGM… More >
Login
Register
Submit a Paper
Propose a Special lssue